This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cosmetic Surgery Stocks Keep Stiff Upper Lip

Allergan's biggest business remains eye-care drugs, which represents 47% of first-half sales and were up 24% over the same period last year. Because Allergan is more reliant on products that receive insurance coverage, analysts say its stock shouldn't be as volatile as those of Mentor and Medicis. However, Allergan isn't free from worry or risk.

Gary Nachman of Leerink Swann recently trimmed his third-quarter sales and earnings forecasts because his research on cosmetic-treatment trends "were more disappointing than we expected" both in the U.S. and in Europe. Although he maintains an outperform rating, he reduced his price target from the high $60s to the mid- to high $50s.

"We remain confident that Allergan can absorb the potential weaknesses in the aesthetic products with solid diversification and financial flexibility," he says in a recent research report. He doesn't own shares.

The diversification includes the obesity-control device Lap-Band, an adjustable clamp that reduces the amount of food the stomach can hold. First-half 2008 sales of $148.5 million represented a 22% gain from last year.

Additionally, Allergan is testing Botox for new uses such as treating overactive bladder and headaches. Botox started as a drug for a rare condition of uncontrolled eye-blinking.

Meanwhile, investors in Medicis were no doubt blinking on Sept. 24 when the company said an accounting error would force a restatement of five years of financial results. The restatement is not expected to affect cash flows and cash balances, Medicis said. The company also withdrew its financial guidance for the rest of the year. The stock is down about 34% since the day before the restatement announcement.

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
MRX $0.00 0.00%
AGN $240.22 1.21%
AAPL $124.24 0.00%
FB $83.37 0.43%
GOOG $555.17 0.00%


DOW 17,678.23 -40.31 -0.23%
S&P 500 2,056.15 -4.90 -0.24%
NASDAQ 4,863.3620 -13.1570 -0.27%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs